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Abstract
Objective
Antibodies against glutamic acid decarboxylase 65 (anti-GAD65) are associated with a number
of neurologic syndromes. However, their pathogenic role is controversial. Our objective was to
describe clinical and paraclinical characteristics of anti-GAD65 patients and analyze their re-
sponse to immunotherapy.
Methods
Retrospectively, we studied patients (n = 56) with positive anti-GAD65 and any neurologic
symptom. We tested serum and CSF with ELISA, immunohistochemistry, and cell-based assay.
Accordingly, we set a cutoﬀ value of 10,000 IU/mL in serum by ELISA to group patients into
high-concentration (n = 36) and low-concentration (n = 20) groups. We compared clinical and
immunologic features and analyzed response to immunotherapy.
Results
Classical anti–GAD65-associated syndromes were seen in 34/36 patients with high concen-
tration (94%): stiﬀ-person syndrome (7), cerebellar ataxia (3), chronic epilepsy (9), limbic
encephalitis (9), or an overlap of 2 or more of the former (6). Patients with low concentrations
had a broad, heterogeneous symptom spectrum. Immunotherapy was eﬀective in 19/27 treated
patients (70%), although none of them completely recovered. Antibody concentration re-
duction occurred in 15/17 patients with available pre- and post-treatment samples (median
reduction 69%; range 27%–99%), of which 14 improved clinically. The 2 patients with un-
changed concentrations showed no clinical improvement. No diﬀerences in treatment
responses were observed between speciﬁc syndromes.
Conclusion
Most patients with high anti-GAD65 concentrations (>10,000 IU/mL) showed some im-
provement after immunotherapy, unfortunately without complete recovery. Serum antibody
concentrations’ course might be useful to monitor response. In patients with low anti-GAD65
concentrations, especially in those without typical clinical phenotypes, diagnostic alternatives
are more likely.
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Autoantibodies against glutamic acid decarboxylase (GAD)
65 have been linked to diﬀerent types of syndromes. These
antibodies are widely used as biomarkers for diabetes mel-
litus type 1 (DM1) diagnosis because they are present in
80% of patients at diagnosis.1,2 However, it is well known
that anti-GAD65 can also be associated with speciﬁc neu-
rologic disorders, including stiﬀ-person syndrome (SPS),
cerebellar ataxia (CA), epilepsy (Ep), and limbic encepha-
litis (LE).3–6
The pathophysiologic role of anti-GAD65 in neuro-
inﬂammation is still unclear. It is hard to understand whether
there is a direct antibody-associated pathogenic eﬀect be-
cause the target antigen is located intracellularly. Moreover,
responses to immunotherapy seem to be poorer than in
patients with neurologic disorders caused by most other
antineuronal antibodies.7,8
In studies evaluating treatment eﬀects in anti–GAD65-
positive patients, methods used are variable, and patient
cohorts are often restricted to one of the speciﬁc clinical
phenotypes.9–11 In addition, some studies describing patients
with neurologic symptoms and anti-GAD65 also include
patients with low antibody concentrations. In these patients,
clinical relevance of anti-GAD65 is questionable because low
antibody concentrations are regularly found among patients
with DM1 (without neurologic symptoms) and rarely in
healthy individuals.1,2,12
The aim of this cohort study is to evaluate the clinical rele-
vance of low and high anti-GAD65 concentrations in patients
with neurologic symptoms, to establish clinically relevant
cutoﬀ values (in serum and CSF), and to evaluate clinical and
serologic treatment responses.
Methods
Patients
We retrospectively included patients with neurologic
symptoms and an increased anti-GAD65 concentration
detected in serum and/or CSF, from January 2015 until June
2018. Anti-GAD65 was routinely detected at the De-
partment of Immunology (Laboratory Medical Immunol-
ogy) of the Erasmus University Medical Center by using
ELISA and reported as negative or positive. Clinical in-
formation was obtained from medical ﬁles. Thirty of 56
patients (54%) were seen by one of the authors.
Glossary
CA = cerebellar ataxia; CBA = cell-based assay; Ep = epilepsy; GAD = glutamic acid decarboxylase; IHC =
immunohistochemistry; IVIg = IV immunoglobulin; LE = limbic encephalitis; mRS = modiﬁed Rankin Scale; SARA = Scale
for the Assessment and Rating of Ataxia; SPS = stiﬀ-person syndrome.
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Standard protocol approvals, registrations,
and patient consents
The institutional review board of the Erasmus University
Medical Center approved the study protocol. Written in-
formed consent was obtained from all patients.
Laboratory tests
Anti-GAD65 was determined in serum and CSF when available,
using 3 assays. Paired serum and CSF samples were used if
possible. Otherwise, serum samples drawn closest to the CSF tap
were used, provided they were preimmunotherapy samples. First,
automated quantitative ELISA was performed according to the
manufacturer’s instructions (Medizym anti-GAD; Medipan,
Berlin, Germany). Calibration curves based on 5 calibrators (5,
18, 35, 120, and 250 IU/mL) were used to infer antibody con-
centrations. Samples were considered positive with anti-GAD65
concentrations above 5 IU/mL. When concentrations were over
250 IU/mL, we tested serial dilutions (1:10; 1:100; 1:1,000; 1:
10,000) and chose the most reliable result (i.e., optical density
value in the linear part of the calibration curve) to determine the
IU/mL end concentration. Second, immunohistochemistry
(IHC) was used as a screening method to determine immuno-
reactivity of patients’ serum (diluted 1:200) or CSF (diluted 1:2)
against rat hippocampal brain tissue. A detailed description can be
found elsewhere.13 GAD65 antibody binding causes a character-
istic staining pattern.13 Finally, cell-based assay (CBA) (Euro-
immun, Lu¨beck, Germany; REF: FA 1022-1005-50) was
performed according to the manufacturer’s instructions, using
human embryonal kidney cells (HEK293) expressing recombi-
nant GAD65. Serum was diluted 1:10, and CSF was used
undiluted.
ELISA provided quantitative results. IHC and CBA were used
as conﬁrmatory qualitative techniques to determine clinically
relevant cutoﬀ values for serum and CSF. Samples positive by
ELISA and conﬁrmed with positive IHC and CBA were con-
sidered high-concentration samples.14 Samples showing a pos-
itive staining pattern on IHC, but no typical GADpattern, were
tested more extensively with commercial and in-house CBAs
using ﬁxed or live cells (Euroimmun kits and in-house CBAs).
Defining clinical phenotypes and clinical
relevance of anti-GAD65
Patients were allocated into 6 groups based on the clinical
phenotypes described in the literature: (1) SPS, (2) CA, (3)
Ep, (4) LE, (5) overlap, and (6) other. The overlap category
consisted of patients who had developed more than 1 anti–
GAD65-associated neurologic syndrome over the disease
course. Patients with LE, presenting with seizures or de-
veloping seizures following LE, were not considered as
overlap syndromes and were all classiﬁed as LE.
After determining cutoﬀ values, patients were classiﬁed into
a high-concentration or low-concentration group. Patients in
the high-concentration group were studied more thoroughly to
assess clinical and serologic response to immunotherapy.
Immunotherapy responses were evaluated by one of the
authors during follow-up or were retrospectively assessed from
medical ﬁles. A seizure frequency reduction of at least 50% was
considered as improvement in patients with Ep. For the other
clinical phenotypes, the modiﬁed Rankin Scale (mRS) score
and the Scale for the Assessment and Rating of Ataxia (SARA)
score were used,15,16 when available. One-point improvement
in the mRS score or 3 points at the SARA score was considered
clinically relevant. In the absence of absolute scores, patients’
and physicians’ evaluations, as measured by the clinical global
impression—improvement scale,17 were taken into account.
Serologic response to treatment was measured comparing
pre- and post-immunotherapy ELISA antibody concen-
trations. A reduction of at least 25% following immunother-
apy was considered a relevant concentration reduction.
Patients with isolated DM1
To explore the spectrum of concentrations of anti-GAD65
antibodies, we also assessed patients with DM1 without neu-
rologic symptoms. At the Department of Immunology of the
Erasmus University Medical Center, sera from 669 patients
were tested for anti-GAD65 between January 2018 and De-
cember 2018. As the reason for testing was often unknown,
ﬁltering based on additional antibody testing for Islet Cell
Cytoplasmic Autoantibodies (ICA) or tyrosine phosphatase
antibodies (anti-IA2) was performed. This way, we selected
samples from 198 patients that were sent speciﬁcally for a sus-
picion of insulin-dependent diabetes mellitus because neurol-
ogists would not request additional islet antigen antibodies.
Seventy-three samples (37%) tested positive for anti-GAD65.
Of these, 37 were analyzed more extensively with quantitative
ELISA, IHC, and CBA. Patients with high concentrations and
positive IHC and CBA (n = 3) were approached to identify
associated neurologic disorders, of whom 2 could be traced.
Statistics
The Fisher exact test was used to compare categorical varia-
bles between the high-concentration and low-concentration
groups. Age, CSF cell count, and protein count were com-
pared with the Mann-Whitney U test. To compare antibody
tests, theMcNemar test was used. pValues less than 0.05 were
considered signiﬁcant.We used SPSS 24.0 and Graph Path 7.0
for analysis and data visualization.
Data availability
Any data not published within this article are available at the
Erasmus University Medical Center. Patient-related data will
be shared on request from any qualiﬁed investigator, main-
taining anonymization of the individual patients.
Results
Laboratory tests
We identiﬁed 71 patients with neurologic symptoms and at
least 1 positive serum or CSF anti-GAD65 test result, of
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whom 56 were included in our study. Eleven patients could
not be reached to collect informed consent, and 4 patients
refused to participate.
The median serum concentration measured with ELISA
was 74,700 IU/mL (n = 54; interquartal range [IQR]
1,350–612,500 IU/mL; range 6–2,130,000 IU/mL), and the
median CSF concentration was 2,430 IU/mL (n = 43; IQR
6–8,810 IU/mL; range 0–83,800 IU/mL). Serum and CSF
samples were drawn a median of 25 months (IQR 6–69
months) and 19 months (IQR 1–69 months) after symptom
onset, respectively.
IHC and CBA showed a high concordance (ﬁgure 1). A cutoﬀ
of 100 IU/mL showed a 100% concordance among tests in
CSF. For serum, with a cutoﬀ value of 10,000 IU/mL, 100% of
low-concentration samples had a negative IHC, and 97% of
high-concentration samples had a positive IHC. Similarly,
100% of high-concentration samples were positive with CBA,
and 96% of low-concentration samples were negative. All
CBAs and IHCs corresponded, except 3 diabetes samples
with positive CBA and negative IHC. In those 3 samples,
ELISA concentrations were between 6,220 and 15,400 IU/
mL. Samples with an unspeciﬁc neuropil staining on IHC
were excluded for calculations. Other antibodies were found
in 1 patient in the high anti-GAD65 concentration (anti-
gamma-aminobutyric acid B receptor [GABAbR]) and 2
patients with low anti-GAD65 concentration (1 anti-
GABAbR and 1 anti-GlyR).
In the DM1 group without overt neurologic symptoms, the
median serum concentration of 68 patients with DM1 (35%
of 192 samples) was 86 IU/mL (IQR 51–3,670 IU/mL; range
15–145,400 IU/mL). Three samples (1.6%) showed an anti-
GAD65 concentration >10,000 IU/mL and also tested posi-
tive by IHC and CBA. The 2 patients traceable had DM1.One
also had multiple other autoimmunities (vitiligo, idiopathic
thrombocytopenic purpura, and thyroiditis), but in both
patients, no neurologic or psychiatric symptoms were present.
Patients
Thirty-six patients were allocated into the high-concentration
group (serum concentration >10,000 IU/mL or CSF con-
centration >100 IU/mL) and 20 patients into the low-
Figure 1 Comparison of laboratory techniques
ELISA concentrations of serum (A and B) and CSF (A and D) of patients with neurologic disorders in comparison to IHC and CBA. Patients identified with dark
gray and yellow squares in A showed a neuropil staining on IHC, instead of the typical GAD pattern. Samples with a neuropil staining and high ELISA
concentration had a positive GAD65-CBA result, whereas CBA was negative for low-concentration samples (A). In B and D, dark gray and yellow dots are used
in both IHC and CBA columns to identify these samples. In the dark gray dotted patients, a different antibody was found. Serum or CSF of the yellow dotted
patients showed a neuropil staining, but no known antibody was found. Serum results from patients with antibody testing for diabetes (DM-1) are shown (C).
Logarithmic transformationwas used for charts. Concordance rates for ELISA, IHC, and CBA are provided for serumandCSF (E). CBA = cell-based assay; GAD =
glutamic acid decarboxylase; IHC = immunohistochemistry.
4 Neurology: Neuroimmunology & Neuroinflammation | Volume 7, Number 3 | May 2020 Neurology.org/NN
concentration group. Clinical characteristics are shown in
table 1.
In the high-concentration group, 34/36 (94%) patients had
a typical anti–GAD-associated neurologic syndrome: SPS (n
= 7), CA (n = 3), Ep (n = 9), LE (n = 9), or an overlap
syndrome (n = 6). In the overlap group, 4 patients initially had
drug-resistant focal Ep and developed CA, SPS, or a combi-
nation of both between 2 and 7 years after seizure onset
(ﬁgure 2). One patient initially had CA and developed SPS 5
years later, and 1 SPS patient developed prominent cerebellar
symptoms 7 years after onset. One patient with LE, no seiz-
ures and associated extralimbic involvement in MRI, had
concomitant GABAbR antibodies, without a tumor. Of the
remaining 2 patients, both with DM type 2, one had a pseudo-
orthostatic tremor, and the other one had optic neuropathy.
In the low-concentration group, 12/20 patients had an al-
ternative diagnosis, including 1 LE with anti-GABAbR and
a pancreatic adenocarcinoma and 1 progressive encephalo-
myelitis with rigidity and myoclonus with anti-GlyR without
an associated tumor, diﬀerent variants of subacute or chronic
polyradiculoneuropathies, and other non–immune-mediated
diseases (glioblastoma, hemispastic syndrome after brain
surgery, multiple system atrophy, or functional disorder). The
remaining 8 patients had chronic Ep, otherwise seronegative
LE or nonspeciﬁc ataxia and gait disorder (see table e-1, links.
lww.com/NXI/A209).
Table 1 Clinical and paraclinical characteristics of the high-concentration and low-concentration groups
High concentration (n = 36) Low concentration (n = 20) p Value
Age at onset, median (IQR; range) 29 (33; 11–80) 52 (22; 5–72) 0.23
Women, n (%) 29 (81) 9 (45) 0.02a
Autoimmune disorders, n (%) 18/32 (56) 14/18 (77) 0.21
DM1, n (%) 14/35 (40) 8/18 (44) 0.78
Other autoimmune disorders, n (%) 11/32 (34) 12/18 (67) 0.04a
Tumors,b n (%) 4/20 (20) 2/10 (20) 1.00
Clinical syndrome
Typical, n (%) 34 (94) 11 (55) 0.0008c,d
SPS, n (%) 7 (19) 2 (10)
CA, n (%) 3 (8) 2 (10)
Ep, n (%) 9 (25) 3 (15)
LE, n (%) 9 (25) 4 (20)
Overlap, n (%) 6 (17) 0 (0)
Other, n (%) 2 (6) 9 (45)
CSF
Pleocytosis, n (%) 6/27 (22) 7/14 (50) 0.09
Cell count, median (IQR; range) 31 (128; 6–310) 18 (102; 11–366) 0.66
Proteins increased, n (%) 8/24 (33) 7/12 (58) 0.175
Protein count, median (IQR; range) 0.38 (0.20; 0.20–1.13) 0.55 (0.54; 0.31–1.24) 0.01a
Oligoclonal bands, n (%) 12/18 (67) 3/5 (60) 0.38
MRI (brain) abnormalities, n (%) 15/32 (46) 5/16 (31) 0.38
Other antibodies, n (%)e 1/35 (3) 2/17 (12) 0.20
Immunotherapy use, n (%) 27/35 (77) 8/19 (42) 0.02a
Abbreviations: CA = cerebellar ataxia; DM1 = diabetes mellitus type 1; Ep = epilepsy; IQR = interquartal range; LE = limbic encephalitis; SPS = stiff-person
syndrome.
a p < 0.05.
b Tumors in the high-concentration group: intestinal lymphoma (1), breast cancer (1), prostate adenocarcinoma (1), and testicular tumor (pathology unknown)
(1). Tumors in the low-concentration group: glioblastoma (1) and pancreatic carcinoma (1).
c p < 0.005.
d Comparing the frequency of typical vs other syndromes between patients with high-concentration or low-concentration samples.
e One patient in the high-concentration group had anti-GABAbR. In the low-concentration group, 1 patient had anti-GlyR and 1 patient had anti-GABAbR.
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Figure 3 shows patients distributed according to their clinical
phenotype and antibody concentration in serum and CSF.
The median concentrations of the diﬀerent clinical pheno-
types (in the high-concentration group) were comparable in
serum (p = 0.210) and CSF (p = 0.067). No association was
found between concentration levels and clinical severity be-
tween patients (data not shown).
Within the high-concentration group, the median serum/CSF
anti-GAD65 ratio was 53 (IQR 171; range 7–1,761, n = 28).
After excluding overlaps, there were no signiﬁcant ratio dif-
ferences between the clinical syndromes (p = 0.29), although
the median ratio of SPS was more than 2-fold that of the other
phenotypes (ﬁgure 3C).
Twenty-seven patients from the high-concentration group were
treated with immunotherapy, of them 26 (96%) received IV
immunoglobulins (IVIg) in diﬀerent treatment regimes. Most
used regime was 0.4 g/kg for 5 days, repeated monthly for at
least 2 more times, to assess response. Eight patients (30%)
were treated with IV methylprednisolone, and 3 patients re-
ceived plasma exchange. Four patients were additionally treated
with second-line immunotherapy, including rituximab (n = 3)
and cyclophosphamide (n = 1). Chronic immunosuppression
was given in 11 patients, consisting of combinations of azathi-
oprine (n = 9), oral steroids (n = 8), mycophenolate mofetil (n
= 5), and cyclosporine (n = 1). Figure 2 shows individual
timelines of the high-concentration group patients treated with
immunotherapy. Nineteen patients (70%) improved. Eight of
10 patients with SPS (including patients with overlap syn-
dromes) improved according to themselves and their physi-
cians, accompanied by the mRS score decrease in 7 of them
(table 2). All patients with CA (including patients with overlap
syndromes) except one felt better and obtained a reduction in
the mRS score. SARA scores improved ≥3 points in the only 2
patients in whom scores were available. In patients with chronic
Ep, >50% seizure frequency reduction was obtained in 4 of 7
patients. Immunotherapy was eﬃcacious in 5 of 7 patients with
LE, and 2 of them had relapses despite chronic treatment.
Those 2 responded to more intensive therapies. Four typical
patient examples are provided in ﬁgure 4.
In 17/36 high concentration patients, pre- and post-treatment
samples were available for comparison. Antibody concentrations
showed a median concentration reduction of 69% (range
27%–99%), and decrease was over 25% in 15 of the 17 serum
samples after immunotherapy (ﬁgure 5). A clear clinical response
was observed in 14 of these 15 treated patients. The 2 patients
without consistent decrease in concentration showed no clinical
improvement. Both had focal Ep for years.
In none of the patients, complete recovery was reached.
Similarly, in none of the patients, antibodies disappeared in
serum. In 6/17 patients with pre- and post-treatment samples,
serum concentrations became lower than 10.000 IU/mL.
Despite periodic or chronic immunotherapy, a stagnation,
both clinically and serologically, was observed after initial
improvement. However, after withdrawal or tapering of
Figure 2 Patients treated with immunotherapy
Disease courses and treatment regimens of the 27 patients that were treated with immunotherapy. In patients with overlapping syndromes, the specific
syndromes are indicated below the gy bar with the corresponding color at the relative time when they were diagnosed. Symbols inside the color bars show
specific treatments or the moment they were initiated. A line with the same color is used for chronic (continuous line) and periodic (discontinuous line)
treatments to show their duration. Symbols on the left side correspond to those in Figure 5.
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immunotherapy symptoms deteriorated, syndromes relapsed,
or concentrations increased in 6 patients (ﬁgure 2 and ﬁgure 4).
Four patients also had relapses or clinical worsening despite
stable chronic or periodic immunotherapy.
Discussion
This study aimed to determine the clinical relevance of
GAD65 antibodies in patients with neurologic syndromes
and evaluate their responses to immunotherapy. We showed
that patients with high anti-GAD65 concentrations pre-
sented with a limited number of speciﬁc neurologic syn-
dromes, whereas the neurologic symptoms observed in
patients with low concentrations were less speciﬁc, neces-
sitating additional investigations. The laboratory tests used
showed a high concordance and a clear cutoﬀ value for the
high and low antibody concentrations. Around two thirds of
the patients responded to immunotherapy, although all in-
completely. The clinical improvement was reﬂected in the
reduction of anti-GAD65 concentrations in both serum
and CSF.
Patients with high antibody concentrations had well-deﬁned
clinical phenotypes that have been classically associated with
GAD65 antibodies, such as stiﬀ-person syndrome, CA, Ep, or
LE. In addition, 1 of 5 patients had overlap syndromes. Re-
markably, in these patients, the relapse tended to present with
diﬀerent phenotypes. Another interesting feature was a dif-
ferent, not previously described phenotype, including pseudo-
orthostatic tremor and optic neuropathy in 2 patients in the
high-concentration group. Unfortunately, these 2 patients
were not seen by one of the authors, so diagnosis and absence
of more typical symptoms should be taken with caution.
From a diﬀerent perspective, patients with low antibody
concentrations presented with a diversity of neurologic syn-
dromes. Some of them had a phenotype that is similar to the
classically anti–GAD65-associated syndromes, which was
probably the reason why anti-GAD65 was requested in these
patients. However, frequently other diagnoses were identiﬁed
in the workup or during the follow-up, like neurodegenerative
diseases or tumors. In these cases, positive ELISA was not
conﬁrmed by IHC or CBA, and concentrations were low and
comparable to those seen in samples tested for type 1 diabetes
mellitus. In these patients, extensive workup to identify other
diseases is warranted, including requesting other antibodies.
Anti-GABAbR antibodies were identiﬁed in a few patients
with high and low concentrations of GAD65 antibodies, in
line with previous studies.18 Around 40% of the patients in
both high- and low-concentration groups had been diagnosed
Figure 3 Antibody concentrations and clinical syndromes
Patients were grouped according to their clinical phenotype into 1 of the 4 classical anti–GAD65-associated syndrome categories, in the overlap or other
category. Serum (A) and CSF (B) ELISA concentrations are shown in a logarithmic scale. Small black dots represent patients with low antibody concentrations.
The specific symptoms of these patients are listed in the supplementary material. Orange dots in the SPS column were patients with progressive enceph-
alomyelitis with rigidity and myoclonus, which is considered an extended form of SPS. (C) Serum/CSF ratio of anti-GAD65 ELISA values within the different
syndromes in the high-concentration group. The blue ribbon represents the ratio-frame where intrathecal antibody synthesis would be expected to start. CA
= cerebellar ataxia; Ep = epilepsy; GAD = glutamic acid decarboxylase; LE = limbic encephalitis; SPS = stiff-person syndrome.
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Table 2 Effects of immunotherapy in patients with high antiglutamic acid decarboxylase 65 concentrations
ID Condition Improved
Before
treatment
Best after
treatment
Improved
mRS
score/
SARA
score
Subjective
improvement CGI-S CGI-I
8 SPS Yes Walked with a walker,
limited by painful spasms
that worsened with
movement. mRS score 3
Cycles and walks
independent or sometimes
with walker. mRS score 2
Yes, 3 to
2/NA
Yes, much
better
4
moderate
2 much
improved
5 SPS Yes Stiff-leg syndrome. Could
walk without assistance.
mRS score 2
Much better with IVIg, but
still increased tonus. mRS
score 1.
Yes, 2 to
1/NA
Yes, much
better
4
moderate
2 much
improved
33 SPS Yes Stiff-leg syndrome.
Unassisted in short
distances, wheelchair and
walker for longer walks
outside home. mRS score 3
Mild stiffness. Very
satisfied. “Sometimes
forgets that she is ill.” mRS
score 1.
Yes, 3 to
1/NA
Yes, much
better
4
moderate
2 much
improved
13 SPS No Walked unassisted,
independent for daily
activities of life, but limited
by leg stiffness, painful
cramps, and lower back
pain. mRS score 2.
Progression halted, but no
improvement. mRS score 2.
No/NA No 3 mild 4 not
improved
22 CA Yes Walked without assistance,
but tandem impossible.
Diplopia and dysmetria.
mRS score 2
Diplopia and hand
dysmetria solved,
subjectively ataxia 50%
improved (still needs
assistance). mR 2
No/yes,
11 to 8
Yes, improved 4
moderate
2 much
improved
9 CA Yes Moderate ataxia,
dysarthria, and dysmetria.
Only short distances with
a walker. mRS score 4.
Ataxia improved, able to
walk 30 m with a stick. mRS
score 3.
Yes, 4 to
3/unknown
Yes 4
moderate
3 mildly
improved
30 CA Yes Ataxia, dysarthria,
nystagmus, and dysmetria;
needs a walker. mRS score
3.
Objective improvement of
static and dynamic stability
measured by a physical
therapist. mRS score 2.
Yes, 3 to
2/unknown
Yes 4
moderate
2 much
improved
18 Ep Yes 7 seizures/d FOA-de´ja`-vu-,
FOIA)
Clusters of days with 1–3
seizures/d, days without
seizures
NA/NA Yes, mildly 4
moderate
3 mildly
improved
6 Ep Yes 40 seizures/mo (FOIA, FOA,
and bilateral tonic-clonic)
2–4 seizures/mo (less
intense)
NA/NA Yes, much
better
4
moderate
2 much
improved
32 Ep Yes Clusters of 1–3 seizures/
d every 3 wk (FOIA)
1–2 seizures/mo (FOIA) NA/NA Yes, much
better
3 mild 2 much
improved
3 Ep Yes 5–10 seizures/mo (FOIA and
FOA)
2 seizures/mo (FOA) NA/NA Yes, improved 3 mild 2 much
improved
36 Ep No Daily seizures (FOIA daily
and bilateral tonic-clonic
often)
No improvement NA/NA No 4
moderate
4 not
improved
23 Ep No Daily FOA (de´ja`-vu), 9 tonic-
clonic seizures/mo
Improved (de´ja`-vu 2–5/wk,
5 tonic-clonic seizures/mo),
but less than 50%
NA/NA Yes, mildly
(insufficient)
4
moderate
3 mildly
improved
16 Ep No 50–60 seizures/mo (FOIA) No improvement NA/NA No 4
moderate
4 not
improved
34 LE Yes Severe cognitive decline,
memory severely impaired,
and unable to recognize
family members
Initial improvement,
recognized family
members. Able to live at
homewith serious cognitive
impairment. Relapse 9 mo
later, without
improvement.
Yes, 5 to
4/NA
Yes 6 very
severe
3 mildly
improved
Continued
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Table 2 Effects of immunotherapy in patients with high antiglutamic acid decarboxylase 65 concentrations (continued)
ID Condition Improved
Before
treatment
Best after
treatment
Improved
mRS
score/
SARA
score
Subjective
improvement CGI-S CGI-I
4 LE Yes Debut: seizures and
cognition (FOA-de´ja`-vu-,
FOIA, bilateral tonic-clonic,
status epilepticus).
Relapses: seizure frequency
increase, status epilepticus,
and cognition.
Clear improvement: seizure
frequency reduced (almost
all FOA), cognition
improved. Worsens with
immunotherapy reduction.
Yes, 5 to
2/NA
Yes, improved 4
moderate
2 much
improved
21 LE Yes Debut: memory
impairment, panic attacks,
seizures (FOA and bilateral
tonic-clonic), and status
epilepticus. Then, chronic
Ep. Relapses: seizure
frequency to 1–2 daily
Seizures and memory
improved during first
admission. Seizures almost
disappeared with chronic
immunotherapy
(occasional FOIA).
Yes, 5 to
1/NA
Yes, much
better
4
moderate
2 much
improved
24 LE Yes Chronic Ep with relapses.
Relapses: seizure frequency
increase (almost daily),
behavioral symptoms;
twice status epilepticus.
1 seizure/wk, lately stable
for 15 mo
Yes, 5 to
2/NA
Yes, much
better
4
moderate
2 much
improved
26 LE Yes Memory impairment and
seizures; clinical
deterioration, unable to
walk or feed herself
No seizures, walks assisted,
and able to eat
(immunotherapy, surgery,
and chemotherapy)
Yes, 5 to
3/NA
Yes, improved 5 severe 3 mildly
improved
29 LE No Seizures (FOIA) and
behavioral symptoms.
Admitted with status
epilepticus.
Chronic treatment-
refractory Ep, no
improvement with
immunotherapy.
No/NA No 4
moderate
4 not
improved
12 LE No Memory impairment and
seizures (FOA-de´ja`-vu- 2/d,
bilateral tonic-clonic twice)
2 seizures/wk (FOA),
memory normalized
Yes, 3 to
1/NA
Yes, much
better
4
moderate
2 much
improved
7 Ep + SPS Yes Seizures (FOA-musicogenic-
, bilateral tonic-clonic) had
variable frequency.
Stiffness in legs, walker.
Serious progression after
immunotherapy
withdrawal (falls, hip
fracture, and continued
spasm), became bedbound.
mRS score 5
Initially: became seizure
free, not much
improvement in stiffness.
Treatment stopped.
Restarted after
progression, with serious
improvement. Needs
walker. mRS score 3
Yes, 5 to
3/NA
Yes, much
better
5 severe 2 much
improved
1 Ep + SPS Yes Seizures 15/wk (FOIA).
Wheelchair due to stiffness
and pain. mRS score 4.
Seizures 1–4/wk (FOIA).
Able to cycle 5 km and
recovered some
independence. mRS score
2.
Yes, 4 to
2/NA
Yes, improved 4
moderate
2 much
improved
2 Ep + SPS +
CA
Yes 4 seizures/mo. Because of
ataxia and stiffness, unable
to walk at all. Wheelchair,
SARA score 22, mRS score 4
No seizures. SARA score 17.
Can walk 12 m with 2
people. mRS score 4. But
subjectively somewhat
better than before
treatment.
No/yes,
22 to 17
Yes, improved 5 severe 3 mildly
improved
28 Ep + SPS Yes Seizures 1/mo (FOIA). Mild
stiffness in the right leg and
arm, walked with
assistance. mRS score 3.
Seizures unchanged (1/mo).
Clear but short-lasting
improvement in stiffness
and spasms after IVIg
infusions. Able to walk
without assistance. mRS
score 2.
Yes, 3 to
2/NA
Yes, improved 4
moderate
2 much
improved
Continued
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with type 1 DM before the onset of neurologic symptoms,
which is also in line with previous studies.19–22
To deﬁne which antibody concentration should be consid-
ered high and relevant, we compared 3 diﬀerent laboratory
techniques and found highly concordant results. ELISA
concentrations above 10,000 IU/mL for serum and 100 IU/
mL for CSF can be detected by IHC and CBA, with com-
parable results. CBA, as expected, is more speciﬁc, especially if
a diﬀerent antibody is concomitantly present in the tested
sample (leading to an unspeciﬁc IHC staining pattern). An-
other cutoﬀ value (of 2,000) has been suggested before,13,23
but these studies used a radioimmunoassay with diﬀerent test
calibration, currently not widely used anymore.
The role of GAD65 antibodies in neuroinﬂammation is de-
batable and still unknown. An obvious theory would be that
antibodies block GAD65, interfering with GABA synthesis
Table 2 Effects of immunotherapy in patients with high antiglutamic acid decarboxylase 65 concentrations (continued)
ID Condition Improved
Before
treatment
Best after
treatment
Improved
mRS
score/
SARA
score
Subjective
improvement CGI-S CGI-I
14 CA + SPS Yes Ataxia and dysmetria and
dizziness (SARA score 11.5)
and stiffness. Needed
a stick at home and awalker
for long distances. mRS
score 4
Dizziness disappeared.
Speech. Ataxia clearly
improved, stiffness mildly
improved. SARA score 7,
stick to go out, unassisted at
home. mRS score 2.
Yes, 4 to
2/NA
Yes, much
better
4
moderate
3 mildly
improved
15 SPS + CA No Severe cerebellar
syndrome, bedbound most
of the time. mRS score 5
Never improved No/
unknown
No 6 very
severe
4 not
improved
Abbreviations: CA = cerebellar ataxia; CGI-I = Clinical Global Impression–Improvement scale: improvement of disease after immunotherapy rated by
a clinician (1—very much improved to 7—very much worse); CGI-S = Clinical Global Impression—Severity scale: severity of the patient’s illness before
immunotherapy rated by a clinician (1—normal to 7—most extremely ill); Ep = epilepsy; FOA = focal onset preserved awareness seizures; FOIA = focal onset
impaired awareness seizures; IVIg = IV immunoglobulin; LE = limbic encephalitis; mRS = modified Rankin Scale; NA = not applicable; SARA = Scale for the
Assessment and Rating of Ataxia; SPS = stiff-person syndrome.
SARA scores are only provided in patients with ataxia, whereas mRS scores are omitted for patients having Ep only.
Figure 4 Disease course and treatment response of 4 patients in the high-concentration group
Horizontal bars containing treatment abbreviations represent the time periods of the corresponding treatments. Blue vertical lines represent seizure
frequency over time. Green discontinuous line connected by green circles shows evolution of serum anti-GAD65 concentration. Thick dark-blue line
connected by rhomboids represents functional status over time, according to the visual score at the rightmost part of the charts. AED= antiepileptic drug; AZA
= azathioprine; GAD = glutamic acid decarboxylase; IVIg = IV immunoglobulin; IVMP = IV methylprednisolone; MMF = mycophenolate mofetil; PDN =
prednisone; RTX rituximab.
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and impairing the inhibitory GABAergic circuits. This would
result in a hyperexcitability state of the CNS. There are studies
supporting this theory, demonstrating a reduced GABA
concentration in the CSF and in the cerebral cortex of patients
with SPS.24,25 However, GAD65 is located intracellularly and
as such not accessible for extracellular antibodies. As an ex-
planation, it has been hypothesized that GAD65 might tran-
siently appear on the cell surface in the synaptic cleft during
the process of neurotransmission and exocytosis.26 In rats, in
vivo injection of GAD65 antibodies from patients with SPS
induced electrophysiologic changes in myelinated neurons,
whereas GAD65 antibodies from patients with DM1 did
not.27 On the other hand, injection of GAD65-speciﬁc T cells
in mice caused death even in mice without B cells.28 This
suggests that the mechanism might be comparable to para-
neoplastic syndromes, in which T cell–mediated responses
primarily lead to symptoms.29 Similarly, despite several
eﬀorts, there are no convincing successful animal models to
support the pathogenicity of GAD65 antibodies.
Moreover, studies report poor responses to immunotherapy
targeting diﬀerent GAD syndromes,6,11,30 as compared to
other neurologic disorders caused by antibodies targeted to
extracellular neuronal structures, again questioning the direct
pathogenic role of anti-GAD65. Although the mechanisms
remain questionable, our results revealed that many patients
show improvement after immunotherapy (mostly IVIg),
coupled to a simultaneous concentration decrease. Many
patients improve not immediately after initiating treatments
but might need some months of treatment before improve-
ment. This might explain some lack of treatment response
from the literature. Repeated doses or combinations of dif-
ferent treatments might be considered before classifying
a patient as a nonresponder. Nevertheless, some of the
patients do not respond at all to immunotherapy. In addition,
it is humbling that even in responders, improvement is gen-
erally incomplete, and often patients have stagnation in both
the clinical and the serologic response after a few months with
chronic immunotherapy. Unfortunately, no patient com-
pletely recovered. A possible explanation might be a combi-
nation of functional and structural neuronal damage, as
diﬀerent research groups have demonstrated in CA.9,30,31
Immunotherapy helps to restore cell function, but cell death is
nonreversible.
Despite clinical stabilization with immunotherapy, treatment
intensity reductions or withdrawals frequently result in clini-
cal progression (in CA) or relapses (in SPS, LE, and Ep). A
few patients have relapses despite stable chronic immuno-
therapy. Fortunately, these patients usually respond to more
intense treatments.
The limitations of this study are mainly linked to its retro-
spective design. In addition, not all patients were seen by one
of the authors. Accordingly, it was sometimes diﬃcult to as-
sess outcome after treatment. Objective parameters such as
mRS score, SARA score, and seizure frequency were used
when applicable. As treatments were open label, a placebo
eﬀect or regression to the mean could explain part of the
results. However, most patients had stable (or slowly pro-
gressive) disease for a longer period and showed a serious
deviation from the time course before. Similarly, the asso-
ciation with concentrations also suggests some real eﬀects.
For future studies, it would be of additional value to study
treatment outcome prospectively by using standardized
questionnaires, examinations, serologic follow-up, and neu-
ropsychological assessments.
To summarize, in patients with classical syndromes (stiﬀ-
person, CA, and encephalitis with seizures), detection of high
Figure 5 Antibody concentration response to immunotherapy
Concentration responses to treatment of the 17
patients of whom pretreatment and posttreat-
ment samples were available. Red lines represent
the patients lacking clinical improvement. The
blue dashed line in the right graph represent CSF
samples obtained pretreatment and at clinical
relapse. A reduction of at least 25% following im-
munotherapy was considered a relevant concen-
tration reduction. GAD = glutamic acid
decarboxylase.
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concentrations of anti-GAD65 is practically diagnostic of an
anti–GAD65-related syndrome. However, depending on the
syndrome (e.g., LE), physicians should consider the possi-
bility of concurrent antibodies, such as GABAbR. These
classical syndromes should be treated with prolonged im-
munotherapy (as the current study suggests). On the other
hand, the presence of atypical syndromes (or nonspeciﬁc
encephalitic syndromes with seizures) or a typical syndrome
but with low-concentration anti-GAD65 should raise concern
for another underlying disease (anti-GAD65 as bystanders).
In these patients, more extensive investigations for alternative
diagnoses should be considered.
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